Table 1 Summary of the data on thyroid lobectomy in low-risk differentiated thyroid carcinoma
From: Lobo-isthmectomy in the management of differentiated thyroid cancer
Study | Number of patients | Source | Main outcomes |
|---|---|---|---|
Studies that ATA took into account preparing 2015 ATA GL | |||
Mendelsohn [17] | 22,724 | SEER | No difference in survival between TT and TL |
Matsuzu [18] | 1088 | Single center | All treated with TL. No comparison between TT and TL 25-year DSS 95.2% |
Nixon [19] | 889 | Single center | No difference in local and regional recurrence between TT and TL No differences in OS and DSS |
Haigh [20] | 5432 | SEER | No differences in survival between TT and TL |
Bilimoria [23] | 52,173 | NCDB | Significantly higher risk of recurrence and death in tumors > 1 cm after TL than TT |
Adam [21] | 61,775 | NCDB | No difference in OS between TT and TL |
Barney [22] | 23,605 | SEER | No differences in OS and DSS between TT and TL |
Studies published after the introduction of 2015 ATA GL | |||
Kuba [25] | 173 | Single center | No differences in RFS and OS between TT and TL |
Song [26] | 2345 | Single center | No difference in DFS between TT and TL |
Choi [27] | 5266 | Single center | Significantly lower DFS after TL than TT. No difference in DSS between TT and TL |
Bosset [29] | 295 | Single center | All treated with TL. No comparison between TT and TL. Recurrence rate 13.6% |
Matsuura [30] | 6259 | Single center | No differences in OS, DSS, and RFS between TT and TL |
Rajjoub [31] | 33,816 | NCDB | TT compared with TL associated with significantly improved survival in tumors 2–3.9 cm, no difference in tumors 1–1.9 cm |